VisMederi

What VisMederi does

VisMederi Srl is an Italian life sciences service company headquartered in Monteriggioni-Siena, with laboratory facilities in Siena and Colle di Val d'Elsa. The company was founded in 2014 (per company website copyright and legal entity records) and operates under a UNI EN ISO 9001:2015 certified quality management system. VisMederi provides a portfolio of bioanalytical and vaccine assessment services — including serological and virological testing, cell culture services, assay development, diagnostic testing, and project management for clinical trials — to pharmaceutical and biotech companies developing vaccines and drugs, as well as to regulatory agencies (EMA, FDA, PMDA) for whom it supports vaccine registration submissions, with a particular focus on seasonal and pandemic influenza. The core technology is wet-lab serological and virological assay work and validated bioanalytical methods used in regulatory filings, rather than software or data products.

VisMederi generates revenue through project-based service contracts with enterprise pharmaceutical clients and regulatory bodies, using a direct sales motion and supplementing commercial activity through EU-funded research consortium participation (e.g., the EUR 148M NOFLU consortium). Pricing is not publicly disclosed. The company's distribution is direct, with a horizontal segmentation that cuts across the vaccine and drug development value chain.

The company sits within a broader group structure that includes VisMederi Holding (parent), VisMederi Life Sciences (core operating subsidiary), VisMederi Diagnostics (adjacent operating subsidiary), and Fondazione VisMederi (non-profit affiliated entity). The group is privately held with no disclosed venture capital funding and no public listing. Headcount is in the 11-50 range, and the company maintains an active social media presence (LinkedIn, Instagram, Facebook, YouTube, Twitter) and a corporate website as its primary marketing channels.

Name

VisMederi

Legal name

VisMederi Srl

Website

https://vismederi.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

VisMederi Srl is an Italian life sciences service company that provides serological, virological, and bioanalytical testing, cell culture services, and clinical trial project management to pharmaceutical companies and regulatory agencies (EMA, FDA, PMDA) for vaccine registration, with a focus on seasonal and pandemic influenza.

Ownership category

akta.pro rank

Product category

Vaccine Assessment & Bioanalytical CRO Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Vaccine assessment services
• Serological testing
• Bioanalytical services
• Clinical trial testing
• Vaccine efficacy evaluation

Headquarters

HQ city

Siena

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

VisMederi is an Italian life sciences company providing vaccine assessment and bioanalytical services. The company's core offerings include serological testing for seasonal and pandemic influenza vaccines in support of regulatory submissions to agencies such as EMA, FDA and PMDA, along with virological testing, cell culture services, diagnostic testing, custom assay development, and project management for clinical trials.

Product overview

VisMederi is a life sciences company offering a unified portfolio of vaccine assessment and bioanalytical services. The core offerings include vaccine analysis and assessment for regulatory agency registration (EMA, FDA, PMDA), with specific focus on serological testing for seasonal and pandemic influenza vaccines. The services portfolio encompasses assay development, project management for clinical trials, diagnostic testing, and COVID-19 related services. All activities are conducted under a UNI EN ISO 9001:2015 quality management system.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccine Assessment Services Analytical testing and evaluation of biological samples for vaccine efficacy and registration, including validation of bioanalytical methods for regulatory agency submissions (EMA, FDA, PMDA). Offered to pharmaceutical companies, biotech firms and regulatory agencies.
• Bioanalytical Services Development of virological and serological testing, diagnostic testing for evaluation of new drug efficacy, cell culture services, and project management for clinical trials. Targeted at pharmaceutical and biotech clients running vaccine and drug development programs.
• Assay Development Custom assay development services for vaccine evaluation and drug efficacy testing, supporting bioanalytical workflows for clients.
• Project Management Division Project management services principally for clinical trials, supporting vaccine and drug development programs run by pharmaceutical and biotech clients.
• Diagnostic Testing Diagnostic testing services used to evaluate vaccine and drug efficacy, supporting client R&D and clinical development activities.
• COVID-19 Services Testing and evaluation services specifically related to COVID-19 vaccine assessment, leveraging the company's serological and virological testing capabilities.
• Quality Management System Company-wide quality management system operating under UNI EN ISO 9001:2015 certification that underpins all laboratory and bioanalytical service delivery.

Quantifiable outcome

• Successfully developed serological tests for registration of seasonal and pandemic influenza vaccines with regulatory agencies

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• EthriscoreStrategic or Co-development Partner · 25 February 2026Part of NOFLU consortium awarded EUR 148 million by European Commission for pandemic influenza mRNA mucosal vaccine development. VisMederi contributes expertise in vaccine assessment and serological testing as part of the 7-organization consortium.
• EvonikcoreStrategic or Co-development PartnerPart of NOFLU consortium (Germany-based partner) working on pandemic influenza vaccine development with EUR 148 million European Commission funding.
• NIVI DevelopmentcoreStrategic or Co-development PartnerPart of NOFLU consortium (Denmark-based partner) collaborating on pandemic influenza vaccine development.
• Statens Serum InstitutcoreStrategic or Co-development PartnerPart of NOFLU consortium (Denmark-based partner) working on pandemic influenza vaccine development with Phase 1 trials at Gentofte Hospital in Copenhagen.
• Bavarian NordiccoreStrategic or Co-development PartnerPart of NOFLU consortium (Denmark-based partner) collaborating on pandemic influenza vaccine development.
• ECRAIDcoreStrategic or Co-development PartnerPart of NOFLU consortium (Netherlands-based partner) working on pandemic influenza vaccine development.
• European UniversitiescoreStrategic or Co-development PartnerCollaborations with universities for life sciences research and vaccine development.
• Pharmaceutical Industry PartnerscoreStrategic or Co-development PartnerPartnerships with pharmaceutical industry for vaccine and drug development projects.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Eurofins Viracor BioPharma Services: Eurofins Viracor provides specialty bioanalytical and vaccine immunology testing to pharma/biotech, including serology, cell-based assays, and clinical trial support. As part of Eurofins, it competes directly with VisMederi on vaccine serology/assessment, but with greater scale and global reach.
• Celerion: Nebraska-based Celerion is a clinical and bioanalytical services CRO with deep expertise in vaccine and biologics bioanalysis, supporting Phase I–III trials and regulatory submissions. Comparable service scope to VisMederi's bioanalytical and project management offerings, though with broader therapeutic area reach.
• Viroclinics-DDL: Viroclinics-DDL (now owned by Q² Solutions / IQVIA-Quest Diagnostics JV) is a Dutch virology and vaccine testing CRO. It directly mirrors VisMederi's serological/virological testing, vaccine assessment, and bioanalytical services for pharma and regulatory agencies — a near one-to-one service overlap.
• Nexelis: Quebec-based Nexelis is a specialty vaccine and biological testing CRO offering immunoassay, serology, and cell-based assay services to vaccine developers and regulators. Its service portfolio, client base (global vaccine pharma + public health agencies), and operating model are highly comparable to VisMederi.

Broad incumbents

• ICON plc: ICON plc, post-PRA Health Sciences acquisition, runs global vaccine and infectious disease clinical development operations including bioanalytical and central lab services. While much larger, its vaccine lab and bioanalytical divisions provide similar service overlaps to VisMederi's mid-tier competitors.
• SGS Health & Nutrition: SGS offers clinical research, bioanalytical, and vaccine testing services through its Health Sciences division, including serology, virology, and cell-based assays. Operates at greater scale and across more geographies than VisMederi, but with overlapping service offerings.
• Charles River Laboratories: Charles River operates a Biologics Services / Vaccine Services business covering bioanalytical, safety, and potency testing for vaccine developers. It is a much larger, listed competitor that overlaps with VisMederi in vaccine assessment and bioanalytical testing.
• Q² Solutions (IQVIA / Quest Diagnostics JV): Q² Solutions is a global clinical lab services JV between IQVIA and Quest Diagnostics with vaccine, immunoassay, and bioanalytical services — most notable for having absorbed Viroclinics-DDL. A relevant benchmark for VisMederi's potential scale-up trajectory.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development / Covance runs global central lab and bioanalytical services for vaccine clinical trials, with extensive immunology and serology capabilities. A much larger player but a credible adjacent incumbent that VisMederi could partner with or compete against for vaccine serology contracts.
• PPD (Thermo Fisher Scientific): PPD, acquired by Thermo Fisher in 2021, is a global full-service CRO with vaccine and infectious disease clinical development capabilities including bioanalytical and laboratory services. VisMederi could partner with or compete against PPD's vaccine lab services at the sub-contracting tier.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/VisMederi
• YouTubeyoutube.com/channel/UCLcosHLHoI2g1Po86kKPlgA
• Facebookfacebook.com/vismederi
• LinkedInlinkedin.com/company/vismederi-srl
• Instagraminstagram.com/vismederi_srl

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VisMederi